Asymchem Laboratories Reports Annual Profit Growth of 19.35%

Stock News03-30

Asymchem Laboratories (06821) announced its financial results for the year ended December 31, 2025. The group recorded revenue of approximately RMB 6.67 billion, representing a year-on-year increase of 14.91%. Net profit attributable to shareholders of the listed company amounted to about RMB 1.133 billion, up 19.35% compared to the previous year. Basic earnings per share were RMB 3.16. The company proposed a dividend of RMB 13.00 per 10 ordinary shares, inclusive of tax.

According to the announcement, the company has adhered to a strategy of deepening relationships with major clients while gradually extending its service chain. During the reporting period, revenue from large pharmaceutical companies reached RMB 2.916 billion, an increase of 8.36% year-on-year. At the same time, Asymchem has focused on broadening its customer base among small and medium-sized enterprises, building a pipeline of potential projects. Revenue from small and medium-sized pharmaceutical companies totaled RMB 3.755 billion, rising 20.57% compared to the prior year, reflecting a trend toward greater diversification in revenue sources.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1125164007?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-30 22:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1125164007","market":"nz","top_or_hot":-1,"title":"Asymchem Laboratories Reports Annual Profit Growth of 19.35%","media":"Stock News","content":"<p>Asymchem Laboratories (06821) announced its financial results for the year ended December 31, 2025. The group recorded revenue of approximately RMB 6.67 billion, representing a year-on-year increase of 14.91%. Net profit attributable to shareholders of the listed company amounted to about RMB 1.133 billion, up 19.35% compared to the previous year. Basic earnings per share were RMB 3.16. The company proposed a dividend of RMB 13.00 per 10 ordinary shares, inclusive of tax.</p>\n<p>According to the announcement, the company has adhered to a strategy of deepening relationships with major clients while gradually extending its service chain. During the reporting period, revenue from large pharmaceutical companies reached RMB 2.916 billion, an increase of 8.36% year-on-year. At the same time, Asymchem has focused on broadening its customer base among small and medium-sized enterprises, building a pipeline of potential projects. Revenue from small and medium-sized pharmaceutical companies totaled RMB 3.755 billion, rising 20.57% compared to the prior year, reflecting a trend toward greater diversification in revenue sources.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Asymchem Laboratories Reports Annual Profit Growth of 19.35%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAsymchem Laboratories Reports Annual Profit Growth of 19.35%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-30 22:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Asymchem Laboratories (06821) announced its financial results for the year ended December 31, 2025. The group recorded revenue of approximately RMB 6.67 billion, representing a year-on-year increase of 14.91%. Net profit attributable to shareholders of the listed company amounted to about RMB 1.133 billion, up 19.35% compared to the previous year. Basic earnings per share were RMB 3.16. The company proposed a dividend of RMB 13.00 per 10 ordinary shares, inclusive of tax.</p>\n<p>According to the announcement, the company has adhered to a strategy of deepening relationships with major clients while gradually extending its service chain. During the reporting period, revenue from large pharmaceutical companies reached RMB 2.916 billion, an increase of 8.36% year-on-year. At the same time, Asymchem has focused on broadening its customer base among small and medium-sized enterprises, building a pipeline of potential projects. Revenue from small and medium-sized pharmaceutical companies totaled RMB 3.755 billion, rising 20.57% compared to the prior year, reflecting a trend toward greater diversification in revenue sources.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"","article_id":"1125164007","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1125164007","pubTimestamp":1774882582,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Asymchem Laboratories (06821) announced its financial results for the year ended December 31, 2025. The group recorded revenue of approximately RMB 6.67 billion, representing a year-on-year increase...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0239":"医药制造","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","BK1191":"制药","BK0132":"高送转概念","06821":"凯莱英","002821":"凯莱英"},"translate_title":"凯莱英医药公布年度利润增长19.35%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06821":1,"002821":1},"content_text":"Asymchem Laboratories (06821) announced its financial results for the year ended December 31, 2025. The group recorded revenue of approximately RMB 6.67 billion, representing a year-on-year increase of 14.91%. Net profit attributable to shareholders of the listed company amounted to about RMB 1.133 billion, up 19.35% compared to the previous year. Basic earnings per share were RMB 3.16. The company proposed a dividend of RMB 13.00 per 10 ordinary shares, inclusive of tax.\nAccording to the announcement, the company has adhered to a strategy of deepening relationships with major clients while gradually extending its service chain. During the reporting period, revenue from large pharmaceutical companies reached RMB 2.916 billion, an increase of 8.36% year-on-year. At the same time, Asymchem has focused on broadening its customer base among small and medium-sized enterprises, building a pipeline of potential projects. Revenue from small and medium-sized pharmaceutical companies totaled RMB 3.755 billion, rising 20.57% compared to the prior year, reflecting a trend toward greater diversification in revenue sources.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1125164007","isCrawlerRequest":true}